BACKGROUND Bolus thrombolytic therapy is a simplified means of administering thrombolysis that facilitates rapid time to treatment. TNK-tissue plasminogen activator (TNK-tPA) is a highly fibrin-specific single-bolus thrombolytic agent. METHODS AND RESULTS In TIMI 10B, 886 patients with acute ST-elevation myocardial infarction presenting within 12 hours were randomized to receive either a sing...

This article reviews the randomized control trials (RCT's) that were published in 2007 of emerging pharmacotherapies in patients with acute (/= 12 weeks) stroke. A Medline search generated 22 RCT's in stroke in the year 2007 in the English language. These trials were primarily efficacy studies. These included the role of statins (an anti-lip...

background : treatment delay in the management of st-elevation myocardial infarction conversely correlates with prognosis and survival of the patients. this study aimed to investigate factors associated with delay in the thrombolytic therapy of these patients in tehran. methods : between 2007 and 2010, the interval between the self-reported time of the onset of symptoms and initiation of the th...

OBJECTIVE Little is known about thrombolytic therapy patterns in patients with ST-elevation myocardial infarction (STEMI) in the Middle East. The objective of this study was to evaluate the clinical profile and mortality of STEMI patients who arrived in hospital within 12 hours from pain onset and received thrombolytic therapy. PATIENTS AND METHODS This was a prospective, multinational, multi...

Thrombolytic therapy accelerates the dissolution of acute pulmonary embolism and is potentially lifesaving. The goal of this article is to offer a critical analysis of the use of thrombolytic therapy in this setting. Guidelines have been written and modified and new ones have been published over the past several years. Although an evidence base exists, unanswered questions remain. Despite the p...

BACKGROUND AND PURPOSE Intracranial hemorrhage is a serious complication of thrombolytic therapy for acute myocardial infarction, especially among the elderly, but little information exists on estimating risk. Better estimation of risk in individual patients may allow for withholding or using alternate therapies among those at highest risk. METHODS To quantify the risk and identify predictors...

The existence of significant synergism between tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA), and between t-PA and urokinase in thrombolysis in vivo is described. In a quantitative preparation of thrombolysis, consisting of rabbits in which a blood clot was induced in the jugular vein with 125I-labeled fibrin, intravenous infusion over 4...

Background: Reactive oxygen species have been implicated in the pathogenesis of ischemic and reperfusion injury. In the current work we have measured malondialdehyde (MDA), total thiols, total CK, CK-MB and AST in ECG proven acute myocardial infarction (AMI) patients immediately after admission and 24 hours after administration of thrombolytic agent streptokinase, and in healthy controls. Metho...

Coronary heart disease is the single largest cause of mortality in the UK with acute myocardial infarction (AMI) being responsible for the greatest amount of deaths. Improving perfusion to the myocardium to prevent further damage or death of the cardiac tissue is the aim of treating AMI. In the UK reperfusion is achieved either through the use of an thrombolytic agent (streptokinase, alteplase,...